SCA
ALZN icon

Sassicaia Capital Advisers’s Alzamend Neuro ALZN Stock Holding History

Sassicaia Capital Advisers’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-69
Closed -$289K – 21
2021
Q3 		$289K Buy
+69
New +$379K 0.82% 25

Other funds holding ALZN

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
EGM
Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sassicaia Capital Advisers's ALZN Position: Q4 2021 in Review

Sassicaia Capital Advisers sold out of Alzamend Neuro (ALZN) in Q4 2021, closing a stake of 69 shares — an estimated $289K sold.

Sassicaia Capital Advisers first reported a position in ALZN in Q3 2021 and held it in 1 quarter. The position peaked at $289K in Q3 2021. 19 funds tracked by Wall St. Rank hold ALZN as of Q4 2021.

  • Sassicaia Capital Advisers reported no remaining Alzamend Neuro position as of Q4 2021 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 69 Alzamend Neuro shares in Q4 2021, an estimated $289K.
  • Sassicaia Capital Advisers first reported a position in Alzamend Neuro in Q3 2021 and held it in 1 quarter.
  • Sassicaia Capital Advisers's Alzamend Neuro position peaked at $289K in Q3 2021.
  • 19 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2021.

Based on Sassicaia Capital Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.